Immuto Scientific Announces $8M Seed 2 Financing and Daiichi Sankyo Collaboration to Uncover a New Class of Therapeutic Targets with Structural Surfaceomics

MADISON, Wis. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 18, 2025--

Immuto Scientific announced today the closing of an oversubscribed $8 million Seed 2 financing round and a drug discovery collaboration with Daiichi Sankyo, a global pharmaceutical company. Immuto Scientific is applying its AI-enabled structural surfaceomics platform to a new approach in drug discovery. Backed by the financing, the company will advance its internal oncology pipeline toward IND-enabling studies and extend the platform into additional areas such as immunology and inflammation.

“The greatest challenge in drug discovery today is not the lack of modalities; it’s the shortage of truly novel, disease‑specific targets,” said Faraz A. Choudhury, Ph.D., co‑founder and CEO of Immuto Scientific. “The vast majority of